These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 31884974

  • 1. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
    Wu H, Li R, Zhang Z, Jiang H, Ma H, Yuan C, Sun C, Li Y, Kong B.
    J Ovarian Res; 2019 Dec 29; 12(1):125. PubMed ID: 31884974
    [Abstract] [Full Text] [Related]

  • 2. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H, Li Y, Wang X, Wu H, Qi G, Li R, Yang N, Gao M, Yan S, Yuan C, Kong B.
    Cell Death Dis; 2019 Feb 18; 10(3):166. PubMed ID: 30778048
    [Abstract] [Full Text] [Related]

  • 3. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
    Xu Y, Zhang Q, Miao C, Dongol S, Li Y, Jin C, Dong R, Li Y, Yang X, Kong B.
    Cancer Med; 2019 Jan 18; 8(1):351-362. PubMed ID: 30565428
    [Abstract] [Full Text] [Related]

  • 4. Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance.
    Marolt N, Pavlič R, Kreft T, Gjogorska M, Rižner TL.
    Biomed Pharmacother; 2024 Aug 18; 177():117069. PubMed ID: 38968802
    [Abstract] [Full Text] [Related]

  • 5. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.
    Gynecol Oncol; 2014 Jun 18; 133(3):591-8. PubMed ID: 24657486
    [Abstract] [Full Text] [Related]

  • 6. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L, Fu R, Liu P, Wang L, Liang W, Zou H, Jia W, Tao L.
    J Ovarian Res; 2021 Nov 04; 14(1):149. PubMed ID: 34736492
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.
    Gynecol Oncol; 2014 Sep 04; 134(3):591-8. PubMed ID: 24995581
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY, Gu LY, Cang W, Cheng MX, Wang WJ, Di W, Huang L, Qiu LH.
    J Exp Clin Cancer Res; 2019 Apr 25; 38(1):176. PubMed ID: 31023317
    [Abstract] [Full Text] [Related]

  • 13. Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance.
    Ni MW, Zhou J, Zhang YL, Zhou GM, Zhang SJ, Feng JG, Xu Q, Zhou Y, Mou HZ, Zheng ZG.
    Biomark Med; 2019 May 25; 13(7):535-543. PubMed ID: 31140829
    [Abstract] [Full Text] [Related]

  • 14. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R, Liu T, Shi J, Luan W, Wei X, Yu J, Mao H, Liu P.
    J Transl Med; 2019 Dec 26; 17(1):428. PubMed ID: 31878941
    [Abstract] [Full Text] [Related]

  • 15. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.
    Drug Resist Updat; 2016 Jan 26; 24():55-69. PubMed ID: 26830315
    [Abstract] [Full Text] [Related]

  • 16. p53 protein aggregation promotes platinum resistance in ovarian cancer.
    Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G.
    Oncogene; 2015 Jul 26; 34(27):3605-16. PubMed ID: 25263447
    [Abstract] [Full Text] [Related]

  • 17. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
    Noriega-Rivera R, Rivera-Serrano M, Rabelo-Fernandez RJ, Pérez-Santiago J, Valiyeva F, Vivas-Mejía PE.
    Int J Mol Sci; 2022 Jul 13; 23(14):. PubMed ID: 35887085
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma.
    Li R, Wu H, Jiang H, Wang Q, Dou Z, Ma H, Yan S, Yuan C, Yang N, Kong B.
    Oncol Rep; 2020 Nov 13; 44(5):2143-2151. PubMed ID: 32901854
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.